Image

A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

Recruiting
Male
Phase N/A

Powered by AI

Overview

The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are:

O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer

Eligibility

Inclusion Criteria:

  • Suspected or diagnosed disease
  • ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old
  • Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line
  • Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line
  • Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment
  • Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization

Exclusion Criteria:

  • Not willing or unable to give written consent
  • Patient not deemed suitable for the study by the researcher approaching the patient

Study details
    Pelvic Fracture
    Prostate Cancer
    Lung Cancer
    Brain Metastasis
    Chronic Subdural Hematoma

NCT07740239

Tampere University Hospital

1 August 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.